KM Research Hub
← 返回论文库
无 KM 图 入排:符合 图源:可得 入排置信度 0.98

Phase III trial of infigratinib versus gemcitabine/cisplatin in adults with advanced cholangiocarcinoma with FGFR2 gene fusion or rearrangement: results and reflections on early termination of PROOF 301.

G K Abou-Alfa, I Borbath, S Roychowdhury, L Goyal, A Lamarca, T Macarulla, R T Shroff, D-Y Oh, C Tamaş, D M Savastano, D F van Veenhuyzen, C Xu, E Freas, J Solanas, M M Javle

ESMO Open 11(4) 106306

PMID41850040
PMCIDPMC13015651
DOI10.1016/j.esmoop.2026.106306
发表日期2026-03-18
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:历史记录已完成可用 Figure 视觉审查,未识别 KM 曲线。
疑似漏检:论文标题/摘要/图注含 OS/PFS/DFS/EFS/survival 等生存终点信号,但当前未得到 KM 提取结果。 已检查 2 张 PMC Figure,均未识别为 KM 图:Figure 1:CONSORT/入组流程图;Figure 2:非 KM 图。
摘要

摘要

BACKGROUND: Infigratinib, an oral fibroblast growth factor receptor (FGFR) 1-3 inhibitor, showed clinical activity and manageable adverse events in the P2 CBGJ398X2204 study and was conditionally approved for adults with previously treated, unresectable, or metastatic cholangiocarcinoma (CCA) with FGFR2 fusion or other rearrangement. PROOF 301, reported in this article, is the confirmatory phase III trial of infigratinib versus gemcitabine plus cisplatin as first-line treatment of FGFR2-rearranged CCA. PATIENTS AND METHODS: Eligible adult patients were randomly assigned in a 2 : 1 ratio to infigratinib 125 mg on days 1-21 of a 28-day treatment cycle versus gemcitabine (1000 mg/m2) + cisplatin (25 mg/m2) on days 1 and 8 of a 21-day cycle. The primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival, investigator-determined PFS, overall response rate (ORR), best overall response, disease control rate, duration of response, and safety. RESULTS: Over 40 months, 1127 patients were pre-screened at 120 sites, and 48 patients were randomly allocated to the study in a 2 : 1 ratio (29 to infigratinib, 19 to chemotherapy). With a target accrual of ∼300 patients, this study was terminated early due to poor accrual. Median PFS (95% confidence interval) by blinded independent central review (BICR) was 7.4 and 8.0 months with infigratinib and chemotherapy, respectively. The ORRs by BICR were 37.9% with infigratinib and 15.8% with chemotherapy. Grade 3-4 adverse events occurred in 79.3% and 58.8% patients treated with infigratinib and chemotherapy, respectively. CONCLUSION: Early termination limited the ability to draw definitive conclusions on the efficacy of infigratinib as first-line treatment of FGFR2-rearranged CCA. This study illustrates the challenges of powering confirmatory studies in biomarker-selected subpopulations of rare tumors and highlights the need for regulatory collaboration to develop pragmatic frameworks for assessing novel therapies in ultra-rare malignancies.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1CONSORT diagram. FGFR, fibroblast growth factor receptor.
非 KM Figure
Figure 2Kaplan–Meier graphs. (A) Survival outcomes (intention-to-treat population): BICR-assessed progression-free survival. (B) Survival outcomes (intention-to-treat population): investigator-assessed progression-free survival. (C) Survival outcomes (intention-to-treat population): overall survival. BICR, blinded independent central review; Gem/Cis, gemcitabine plus cisplatin.
非 KM Figure